This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Biotech Stocks to Add to your Portfolio Post Q2 Earnings
by Arpita Dutt
Here is a look at four biotech stocks including Gilead (GILD) that topped estimates in Q2 and are witnessing upward estimate revisions for the current year.
Alexion's (ALXN) Soliris' Label Expansion Approved in Europe
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) announced that the European Commission (EC) approved a label expansion of lead drug Soliris which should further boost sales.
Mylan Finalizes Settlement Agreement with DOJ for $465M
by Zacks Equity Research
Mylan N.V. (MYL) signed an agreement with the U.S. Department of Justice (DOJ) and two other relators to finalize the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017.
AbbVie's HCV Combo Drug Mavyret Clinches Approval in Canada
by Zacks Equity Research
AbbVie (ABBV) announces Mavyret's sanction in Canada for treatment of HCV across all major genotypes. This gain serves a big boost to the company's product portfolio.
Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada
by Zacks Equity Research
Gilead Sciences, Inc.'s (GILD) HCV portfolio receives a boost with the approval of Vosevi in Canada.
Pfizer's (PFE) Besponsa Gets FDA Nod with a Boxed Warning
by Zacks Equity Research
Pfizer, Inc.'s (PFE) leukemia candidate, Besponsa received FDA approval, though with a boxed warning on the label.
Regeneron's (REGN) RSV Drug Suptavumab Fails NURSERY Trial
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) announced disappointing results from a phase III study, NURSERY Pre-term on suptavumab .
Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL)
by Zacks Equity Research
Mylan (MYL) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Biotech Stock Roundup: Regeneron Drops RSV Antibody, Gilead HIV Drug Gets Priority Review
by Arpita Dutt
This week, companies like Regeneron (REGN) and Ionis provided updates on their pipeline while Gilead announced priority review for its HIV drug.
Zacks.com featured highlights: Coca-Cola FEMSA, Banco Bilbao Vizcaya Argentaria, Lantheus Holdings, Gilead Sciences and Lam Research
by Zacks Equity Research
Zacks.com featured highlights: Coca-Cola FEMSA, Banco Bilbao Vizcaya Argentaria, Lantheus Holdings, Gilead Sciences and Lam Research
Mallinckrodt (MNK) Looks Strong on Acthar, Generics Weak
by Zacks Equity Research
Mallinckrodt undertaking strategic acquisitions and divestitures to evolve as a high-performing specialty pharmaceutical company.
Zacks.com featured highlights: Broadcom Limited, CBRE Group, Sandvik AB, Applied Materials and Gilead Sciences
by Zacks Equity Research
Zacks.com featured highlights: Broadcom Limited, CBRE Group, Sandvik AB, Applied Materials and Gilead Sciences
Gilead (GILD) NDA for HIV Combo Regimen Gets Priority Review
by Zacks Equity Research
Gilead Sciences, Inc.'s(GILD) NDA for an investigational, fixed-dose combination of bictegravir for the treatment of HIV-1 infection obtained priority review.
5 Discounted PEG Stocks for GARP Investors
by Zacks Equity Research
PEG ratio is categorized under value investing and follows the principles of both growth and value investing.
Forget Teva (TEVA), Buy These 4 Drug Stocks Instead
by Arpita Dutt
With generic drugmakers like Teva (TEVA) under pressure, here is a look at four drug stocks that look well-positioned.
Markets Remain Choppy on Continuing Conflicts: 5 Top Picks
by Supriyo Bose
ROE helps investors distinguish between profit-generating companies from profit burners and is useful for determining the financial health of a company.
Alnylam (ALNY) Q2 Loss Narrower than Expected, Sales Miss
by Zacks Equity Research
Alnylam's (ALNY) second-quarter results were mixed with the company reporting a narrower-than-expected loss but sales missed estimates.
Top Ranked Income Stocks to Buy for August 10th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, August 10th:
Valeant (VRX) Beats Q2 Earnings, Sales in Line, Trims View
by Zacks Equity Research
Valeant's (VRX) second-quarter results were encouraging but the company trimmed its guidance due to recent divestitures.
Mylan (MYL) Misses on Q2 Earnings & Sales, Lowers View
by Zacks Equity Research
Mylan N.V. (MYL) reported disappointing second-quarter 2017 results wherein both earnings and sales missed estimates. The company also lowered its guidance.
Prothena (PRTA) Q2 Loss Narrows as Roche Makes $30M Payment
by Zacks Equity Research
Prothena Corporation plc (PRTA) reported a narrower-than-expected loss in the second quarter as the company received a milestone payment from Roche.
Mallinckrodt (MNK) Tops Q2 Earnings, Generics Segment Weak
by Zacks Equity Research
Mallinckrodt Public Limited Company (MNK) reported second-quarter 2017 results wherein earnings beat expectations but sales missed the same.
Forget Bayer, Buy These 3 Drug Stocks Instead
by Arpita Dutt
With Bayer (BAYRY) reporting mixed results in the second quarter and lowering its outlook, here is a look at 3 drug stocks which look well positioned.
Drug Stocks Q2 Earnings Roster for Aug 8: ACAD, JAZZ & More
by Zacks Equity Research
A look at the pharma/biotech companies that are set to report second-quarter results on Aug 8.
Top Ranked Momentum Stocks to Buy for August 7th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 7th: